Ahn A, Park S-S, Kim Y, Lee JY, Lee J-M, Jung J, Kim M, Min C-K. Minimal residual disease assessment in transplant-eligible patients with multiple myeloma: real-world applications of multiparametric flow cytometry-DURAClone (CAREMM-2104). haematol [Internet]. 2024Dec.1 [cited 2025Jul.10];109(12):4100-5. Available from: https://haematologica.org/article/view/haematol.2024.285278